drugset / Trial / NCT03875560
IC14 in Adult Patients With Dengue Fever
RandomizedFactorialTriple-blindTreatment
Summary
Randomized, double-blind, placebo-controlled, safety, PK/PD and preliminary efficacy study of intravenous IC14 in adult patients in a dengue-endemic region presenting with fever \> 38°C for \< 48 hours with a positive NS1 strip assay or reverse-transcriptase polymerase chain reaction assay for dengue virus.
Timeline
- Start
- 2019-05
- Primary completion
- 2020-01
- Completion
- 2020-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IC14 | Monoclonal antibody | 0.5 mg/kg | Intravenous |
| Subject | IC14 | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | IC14 | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | IC14 | Monoclonal antibody | 4 mg/kg | Intravenous |
| Subject | IC14 | Monoclonal antibody | 8 mg/kg | Intravenous |